Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

China unexpectedly cuts reverse repo rate by most in five years to support virus-hit economy

share with twitter share with LinkedIn share with facebook
share via e-mail
03/30/2020 | 01:10am EDT
Man wearing a mask walks past the headquarters of the People's Bank of China, the central bank, in Beijing

China's central bank unexpectedly cut the rate on reverse repurchase agreements by 20 basis points on Monday, the largest in nearly five years, as authorities ramped up steps to relieve pressure on an economy ravaged by the coronavirus pandemic.

The People's Bank of China (PBOC) announced on its website that it was lowering the 7-day reverse repo rate <CN7DRRP=PBOC> to 2.20% from 2.40%, but it did not give a reason for the move.

Ma Jun, a central bank adviser told state media that China still has ample room for monetary policy adjustment and the rate decision took into consideration the return of Chinese companies to work, the global virus situation and a deterioration in the external economic environment.

It was the third cut in the 7-day rate since November, and comes as the coronavirus infections in China - where the outbreak originated late last year - has slowed from a peak in February. The country has so far reported 3,304 deaths from 81,470 infections.

In a note to clients, Capital Economics said "a lot more easing will be needed, especially on the fiscal front, to help the economy return to its pre-virus trend."

Global policymakers have rolled out unprecedented stimulus measures in the past few weeks, cutting rates sharply and injecting trillions of dollars to backstop their economies as many countries have been put under tight lockdowns to contain the pandemic.

Yan Se, chief economist at Founder Securities in Beijing, said the rate cut was China's commitment to a pledge it made during the Group of 20 major economies meeting last week to combat the coronavirus and stabilize financial markets.

"China was the only major economy that had not yet implemented large-scale easing measures" Yan said, noting that many other nations have implemented more drastic steps such as quantitative easing and deeper cuts to benchmark rates.

Leaders of the G20 pledged on Thursday to inject over $5 trillion into the global economy to limit job and income losses from the coronavirus, which has so far infected more than 700,000 people and killed nearly 34,000 worldwide.

Earlier in the day, the PBOC injected 50 billion yuan ($7 billion) into money markets through seven-day reverse repos, breaking a hiatus of 29 trading days with no fresh fund injections.

Chinese 10-year government bond futures initially responded positively to the cut, with the most-traded contract for June delivery rising as much as 0.23%, before pulling back to last trade down 0.1%.

Xing Zhaopeng, markets economist at ANZ in Shanghai, said the latest cut follows the ruling Communist Party's Politburo meeting last Friday.

"The medium-term lending facility (MLF) rate and Loan Prime Rate (LPR) will be cut at the same pace this month. We believe this cut is a signal to urge all loans to refer LPR as the benchmark so that the PBOC can improve the effectiveness of monetary policy transmission," he said.

At Friday's meeting, the politburo said the government will step up policy measures and tighten enforcement in a bid to achieve full-year economic and social development targets.

The coronavirus hit the Chinese economy just as it was starting to show some signs of stabilizing after growth cooled last year to its slowest pace in nearly 30 years amid a trade war with the United States.

Analysts expect China's economy to contract sharply in the first quarter due to widespread disruptions to business and consumer activity caused by the virus as authorities put in place tough public measures to contain the pandemic.

Nomura has lowered its annual GDP growth forecast for China to 1.0% this year, from 1.5% previously, and adjusted quarterly GDP forecasts to a 9.0% annual contraction, from an earlier prediction of 0.9% contraction.

(Reporting by Winni Zhou, Lusha Zhang and Andrew Galbraith; Editing by Kim Coghill & Shri Navaratnam)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
01:43aNOVARTIS : study reveals that migraine support in the workspace can significantl..
PU
05/21GLOBAL MARKETS LIVE: Apple and Google unveil their Covid-19 contact tracing s..
05/21NOVARTIS AG : UBS reaffirms its Neutral rating
MD
05/20NOVARTIS : AveXis receives EC approval and activates 'Day One' access program fo..
AQ
05/19More Than 150 Companies Call for Green Coronavirus Recovery
DJ
05/19NOVARTIS : Zolgensma Gets Conditional EU Approval
DJ
05/17Temporary layoff schemes no cure-all in slow COVID recovery
RE
05/14NOVARTIS : Sandoz Glatopa demonstrates trend towards lower relapse rates and cos..
AQ
05/11NOVARTIS AG : UBS reaffirms its Neutral rating
MD
05/08NOVARTIS AG : Sell rating from JP Morgan
MD
More news
Financials (USD)
Sales 2020 50 047 M
EBIT 2020 15 196 M
Net income 2020 9 407 M
Debt 2020 17 505 M
Yield 2020 3,65%
P/E ratio 2020 20,7x
P/E ratio 2021 17,3x
EV / Sales2020 4,11x
EV / Sales2021 3,79x
Capitalization 188 B
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 100,41 $
Last Close Price 85,50 $
Spread / Highest target 51,5%
Spread / Average Target 17,4%
Spread / Lowest Target -9,97%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-9.56%188 520
JOHNSON & JOHNSON-1.03%380 356
ROCHE HOLDING AG10.48%303 907
PFIZER, INC.-4.29%208 306
MERCK & CO., INC.-16.03%192 766
ABBVIE INC.4.02%162 312